… proinflammatory cytokines in familial Mediterranean fever (FMF)… the efficacy and safety
of canakinumab in all adolescent and … is the good efficacy of canakinumab in 5 anakinra-resistant …

… Shortly after that, the efficacy of Anakinra in the treatment of a colchicine resistant 68 year
old woman homozygous for the M694 V mutation of the MEFV gene [43] and a 15 year-old …

… The aim of the present study was to assess the efficacy and safety of anakinra for the treatment
of colchicine-resistant … in children and adolescents. Rheumatol Int 2015;35:1733–7. 30. …

… treatment of patients with colchicine-resistant FMF and FMF patients … was observed after
initiation of anakinra. In five patients, … in adolescents and adults with colchicine-resistant familial …

… one-fifth of the patients are children and adolescents. Out of 463 MEFV mutation-specified …
trial to explore the safety and efficacy of anakinra in colchicine-resistant FMF patients. It was …

… Twenty-seven per cent of patients were previously treated with biologics, mainly anakinra. …
associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann …

… to investigate the safety and efficacy of IL-1-blocking therapy in colchicine-resistant FMF and
in … The treatment of colchicine-resistant FMF with anakinra and canakinumab was safe and …

… -1 receptor antagonist anakinra for colchicine-resistant FMF … series of colchicine-resistant
Familial Mediterranean fever patients … nine adolescent and adult FMF patients. They treated the …

… trial with anakinra in FMF patients who were colchicine resistant was published (…
colchicine-resistant familial Mediterranean fever. They also showed that IL-1 inhibition is an …

… achieved good outcomes about effectiveness and safety [20]. Anakinra and canakinumab
are … Anakinra and canakinumab succeeded in complete remission in more than two-third of …